[go: up one dir, main page]

JP2579729B2 - Nitroglycerin plaster and method for producing the same - Google Patents

Nitroglycerin plaster and method for producing the same

Info

Publication number
JP2579729B2
JP2579729B2 JP4510428A JP51042892A JP2579729B2 JP 2579729 B2 JP2579729 B2 JP 2579729B2 JP 4510428 A JP4510428 A JP 4510428A JP 51042892 A JP51042892 A JP 51042892A JP 2579729 B2 JP2579729 B2 JP 2579729B2
Authority
JP
Japan
Prior art keywords
nitroglycerin
weight
mixture
acrylate
plaster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP4510428A
Other languages
Japanese (ja)
Other versions
JPH06506944A (en
Inventor
ボイトナー,ディーター
クノベルスドルフ,ファウ.ヘニング
ボルフ,ハンス−ミヒャエル
ホフマン,ライナー
メコニ,ラインホルト
ペーター クライン,ロベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eru Tee Esu Rooman Terapii Shisuteeme Unto Co KG GmbH
SHUBARUTSU FUARUMA AG
Original Assignee
Eru Tee Esu Rooman Terapii Shisuteeme Unto Co KG GmbH
SHUBARUTSU FUARUMA AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eru Tee Esu Rooman Terapii Shisuteeme Unto Co KG GmbH, SHUBARUTSU FUARUMA AG filed Critical Eru Tee Esu Rooman Terapii Shisuteeme Unto Co KG GmbH
Publication of JPH06506944A publication Critical patent/JPH06506944A/en
Application granted granted Critical
Publication of JP2579729B2 publication Critical patent/JP2579729B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to a dermal plaster for the transdermal administration of nitroglycerin, consisting of, besides a support film and a removable protective film, a nitroglycerin-containing, in particular adhesive, composition based on a crosslinked acrylate/vinyl acetate copolymer whose monomer mixture employed for the polymerisation contains 21 to 40 % by weight of vinyl acetate, 55 to 70 % by weight of a C2-8-alkyl acrylate and 3 to 10 % by weight of a C2-4-hydroxyalkyl acrylate and which is crosslinked after admixture of a conventional crosslinker and the nitroglycerin additionally by heating and removing solvents which are present. The specific adhesive composition according to the invention has not only a high absorption capacity but also a high and controllable release capacity for nitroglycerin so that the release area of the plaster necessary for the amount released each day can be kept small, and thus the costs of the plaster are very low. At the same time, owing to the simple adhesive composition, the preparation process is simplified, the addition of other substances to increase the transepidermal transport of substances is unnecessary and thus the costs of the plaster are further kept low and the risk of skin irritation is avoided.

Description

【発明の詳細な説明】 本発明は、支持体フィルム、及び架橋されたアクリレ
ートコポリマーを基礎としてのニトログリセリン含有接
着剤を含んで成る、ニトログリセリンの経皮投与のため
の皮膚膏薬に関する。膏薬はまた、使用の前、すなわち
皮膚へのその適用の前、剥離することによって除去され
る保護フィルムを有する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a dermal plaster for transdermal administration of nitroglycerin, comprising a support film and a nitroglycerin-containing adhesive based on a crosslinked acrylate copolymer. The plaster also has a protective film that is removed by peeling before use, ie before its application to the skin.

ニトログリセリンの経皮投与のための多くの皮膚膏薬
が知られている。たとえばDE2135533及びDE3315272は、
多くの層から構築され、そして活性剤の供給を調節する
膏薬を開示する。ニトログリセリンは、調節膜を通して
単一層リザーバー(DE2135533)から又は複数層レザー
バーの特定の企画(DE3315272)により、種々の機構に
よって開放される。複数層皮膚膏薬は特に製造するのに
ひじょうに費用がかかるので、最近、支持体フィルムの
他に単一層から成るペースト膏薬が開発されて来た。十
分なニトログリセリンの皮膚への吸収及び再び適切な供
給を可能にするために、活性物質の吸収性、活性物質の
供給及び皮膚への接着性質に関して種々の性質を有する
種々の粘着接着剤物質が開発されて来た。たとえば次の
特許明細書に言及されている:GB出願第2095108号、DE O
S第3231400号、GB出願第2086224号、EP出願第0062682
号、EP第85903926.5号、EP第86902978.5号、EP第028550
号、EP第0272562号、US第4608249号及びDE PS第3200369
号。使用される材料及び架橋の程度に依存して、膏薬は
ニトログリセリンのための種々の吸収能力及び供給能力
を有し、そして皮膚への接着能力を変えることによって
特徴づけられる。種々の皮膚適合性がまた相当の役割を
演じる。多くの膏薬はまた、物質の経皮輸送を高めるた
めの物質(すなわち再吸収促進剤)を含む。
Many skin plasters for transdermal administration of nitroglycerin are known. For example, DE2135533 and DE3315272 are
Disclosed is a plaster constructed from a number of layers and regulating the delivery of the active agent. Nitroglycerin is released by various mechanisms, either from a single-layer reservoir (DE2135533) through a regulatory membrane or with the specific design of a multi-layer reservoir (DE3315272). Since multi-layer skin plasters are particularly expensive to manufacture, paste plasters consisting of a single layer in addition to the support film have recently been developed. In order to allow sufficient nitroglycerin to be absorbed into the skin and again to be properly supplied, various adhesive materials having different properties with respect to the absorption of the active substance, the supply of the active substance and the adhesive properties to the skin have been developed. Has been developed. For example, reference is made to the following patent specification: GB Application No. 2095108, DE O
S No. 3231400, GB Application No. 2086224, EP Application No. 0062682
No., EP 85903926.5, EP 86902978.5, EP 028550
No., EP 0272562, US 4608249 and DE PS 3200369
issue. Depending on the materials used and the degree of cross-linking, plasters have different absorption and delivery capabilities for nitroglycerin and are characterized by varying their ability to adhere to the skin. Various skin compatibility also play a significant role. Many salves also contain a substance (ie, a resorption enhancer) to enhance the transdermal transport of the substance.

膏薬の開放表面が1日当たり開放される必要な量を伴
って小さく、そして従って膏薬の価格ができるだけ安い
ように、できるだけ高い吸収能力を有するのみならず、
またニトログリセリンのための高い供給能力を有する、
ニトログリセリンの経皮投与のための皮膚膏薬を供給す
ることが本発明の目的である。同時での特定の接着剤の
使用が製造工程を簡単にし、それを安価にし、そして再
吸収促進剤の添加に基づいて節約せしめる。同時での医
薬製剤のこの単純化は、皮膚刺激の危険性及び/又は接
着剤本体におけるニトログリセリン濃度の調節不可能な
変化の危険性を減じ、ここで前記危険性は時々、皮膚中
への接着剤からの再吸収促進剤の侵入を伴う。
Not only has the absorption capacity as high as possible, so that the open surface of the plaster is small with the required amount to be opened per day and thus the price of the plaster is as low as possible.
Also has a high supply capacity for nitroglycerin,
It is an object of the present invention to provide a skin plaster for transdermal administration of nitroglycerin. The use of a specific adhesive at the same time simplifies the manufacturing process, makes it less expensive and saves on the basis of the addition of resorption accelerators. This simplification of the pharmaceutical preparation at the same time reduces the risk of skin irritation and / or the risk of uncontrollable changes in the nitroglycerin concentration in the adhesive body, wherein said risk is sometimes This is accompanied by penetration of the resorption promoter from the adhesive.

支持体箔、架橋されたアクリレート−酢酸ビニルコポ
リマーに基づく、ニトログリセリン含有接着剤及び従来
の除去可能な保護フィルムを含んで成る。ニトログリセ
リンの経皮投与のための本発明の皮膚膏薬であって、こ
こで前記ニトログリセリン含有接着剤物質は、有機溶媒
における、モノマー100重量%に基づいて酢酸ビニル21
〜40重量%、アクリル酸−C2-8−アルキルエステル55〜
70重量%及びアクリル酸−C2-4−ヒドロキシルアクリル
エステル3〜10重量%から成る混合物の第1段階におけ
るラジカル重合、有機溶媒における従来の架橋剤及び膏
薬に使用するために必要とされる量でのニトログリセリ
ンの第2段階における混合(必要なら有機溶媒におい
て)及び前記得られた混合物又は特定のアクリレート−
酢酸ビニルコポリマーの加熱による架橋及び使用される
有機溶媒又は溶媒の混合物の第3段階における除去によ
り得られ、そして前記得られたニトログリセリンが特定
のアクリレート−酢酸ビニルコポリマーの続く及び追加
の架橋による特定の態様で接着剤物質に構築されること
を特徴とする。前記アクリレート−酢酸ビニルコポリマ
ーは、3.0〜4.2の相対粘度を有する。
It comprises a support foil, a nitroglycerin-containing adhesive based on a crosslinked acrylate-vinyl acetate copolymer, and a conventional removable protective film. A dermal patch of the present invention for transdermal administration of nitroglycerin, wherein the nitroglycerin-containing adhesive material is based on 100% by weight of monomer in an organic solvent.
~ 40% by weight, acrylic acid- C2-8 -alkyl ester 55 ~
Radical polymerization in a first stage of a mixture consisting of 70% by weight and 3-10% by weight of acrylic acid- C2-4 -hydroxylacrylic ester, the amount required for use in conventional crosslinkers and salves in organic solvents. Of the nitroglycerin in the second stage (in an organic solvent if necessary) and the resulting mixture or a specific acrylate
Cross-linking of the vinyl acetate copolymer by heating and removal of the organic solvent or mixture of solvents used in the third stage, and the resulting nitroglycerin is identified by subsequent and additional cross-linking of the particular acrylate-vinyl acetate copolymer Characterized in that it is built into an adhesive material in the manner described above. The acrylate-vinyl acetate copolymer has a relative viscosity between 3.0 and 4.2.

好ましくは、モノマーの混合物は、酢酸ビニルの他に
2−エチルヘキシルアクリレート及びヒドロキシエチル
アクリレートを含む。好ましくは、特定のアクリレート
−酢酸ビニルコポリマーの続く架橋は、ブチルポリチタ
ネート及び/又はアセチルアセトナトチタンから成るチ
タン酸エステル0.3〜3重量%により行なわれる(前記
重量は、コポリマーの重量に対してである)。
Preferably, the mixture of monomers comprises 2-ethylhexyl acrylate and hydroxyethyl acrylate in addition to vinyl acetate. Preferably, the subsequent crosslinking of the particular acrylate-vinyl acetate copolymer is effected with 0.3 to 3% by weight of a titanate consisting of butyl polytitanate and / or titanium acetylacetonato, said weight being based on the weight of the copolymer. is there).

本発明の膏薬の製造方法は、膏薬の使用のために必要
とされる量でのニトログリセリン及び従来の架橋剤又は
架橋剤の従来の混合物を含み、そして酢酸ビニル21〜40
重量%、アクリル酸−C2-8−アルキルエステル55〜70重
量%及びアクリル酸−C2-4−ヒドロキシルアルキルエス
テル3〜10重量%から成るモノマーの混合物のラジカル
重合により得られる、コポリマーの溶液が、膏薬の保護
フィルムに必要な層の厚だけ適用され、そして溶媒又は
溶媒の混合物が加熱により除去され、それによって特定
のアクリレート−酢酸ビニルコポリマーの追加の架橋が
行なわれることを特徴とする。
The process for preparing the plaster of the present invention comprises nitroglycerin and a conventional crosslinker or a conventional mixture of crosslinkers in the amounts required for the use of the plaster, and comprises 21-40 vinyl acetate.
Wt%, -C acrylate 2-8 - alkyl esters 55-70% by weight and -C acrylate 2-4 - obtained by radical polymerization of a mixture of monomers consisting of hydroxy alkyl esters 3-10% by weight, solution of the copolymer Is applied to the protective film of the plaster for the required layer thickness, and the solvent or mixture of solvents is removed by heating, thereby effecting additional crosslinking of the particular acrylate-vinyl acetate copolymer.

好ましくは、前記方法は、アクリレート−酢酸ビニル
コポリマー、ニトログリセリン及び架橋剤が、エタノー
ル又はエタノール−メタノール混合物20〜40重量%を含
む溶媒に溶解され、そして固形分が特定のアクリレート
−酢酸ビニルコポリマー、架橋剤及びニトログリセリン
の混合物40〜60重量%から成ることを特徴とする。
Preferably, the method comprises dissolving the acrylate-vinyl acetate copolymer, nitroglycerin and the crosslinker in a solvent comprising 20 to 40% by weight of ethanol or an ethanol-methanol mixture, and having a solids content of the particular acrylate-vinyl acetate copolymer, It is characterized in that it comprises 40 to 60% by weight of a mixture of a crosslinking agent and nitroglycerin.

〈実施態様〉 本発明のニトログリセリンの経皮投与のための皮膚膏
薬の製造方法及び出発混合物の量は100m2に関して言及
される。
The amount of preparation and starting mixture of skin patches for transdermal administration of nitroglycerin <embodiments> The present invention is referred to with respect to 100 m 2.

油形でのニトログリセリン4.00kgを、アクリレート−
酢酸ビニルコポリマーの40%(w/w)溶液16.00kgに集中
的混合を伴ってゆっくり添加した。次に、その混合物を
攪拌により均質化した。その結果、この接着剤溶液中、
ニトログリセリンの20%(w/w)溶液が得られた。
4.00 kg of nitroglycerin in oil form was
It was added slowly with intensive mixing to 16.00 kg of a 40% (w / w) solution of vinyl acetate copolymer. Next, the mixture was homogenized by stirring. As a result, in this adhesive solution,
A 20% (w / w) solution of nitroglycerin was obtained.

アクリレート−酢酸ビニルコポリマーを次のようにし
て調製した: 酢酸ビニル112g、2−エチルヘキシルアクリレート27
0g、ヒドロキシエチルアクリレート20g、アゾジイソブ
チロニトリル1.4g及び酢酸エチル407gの合計量のうち、
酢酸ビニル112g、2−エチルヘキシルアクリレート39
g、ヒドロキシエチルアクリレート3g及びアゾジイソブ
チロニトリル0.5gを、酢酸エチル115gに添加し、そして
加熱還流した。成分の残留部分を、一定の還流を伴って
4時間にわたって添加した。重合の完結の後、その混合
物を室温に冷却した。得られた接着剤ポリマー溶液は、
ブルックフィールド粘度計により測定される場合、25℃
で5300mPa.sの粘度を有し、47.9%の固形割合及び3.1の
相対粘度を有した。
An acrylate-vinyl acetate copolymer was prepared as follows: 112 g vinyl acetate, 2-ethylhexyl acrylate 27
0 g, 20 g of hydroxyethyl acrylate, 1.4 g of azodiisobutyronitrile and 407 g of ethyl acetate,
112 g of vinyl acetate, 2-ethylhexyl acrylate 39
g, 3 g of hydroxyethyl acrylate and 0.5 g of azodiisobutyronitrile were added to 115 g of ethyl acetate and heated to reflux. The remaining portion of the components was added over 4 hours with constant reflux. After completion of the polymerization, the mixture was cooled to room temperature. The resulting adhesive polymer solution is
25 ° C as measured by Brookfield viscometer
Had a viscosity of 5300 mPa.s, a solids fraction of 47.9% and a relative viscosity of 3.1.

この溶液に、アセチルアセトナトチタン1.35g及び十
分なエタノール又はエタノール−酢酸エチル混合物を添
加し、生成物中の固形分を40%に調節した。
To this solution was added 1.35 g of titanium acetylacetonato and sufficient ethanol or a mixture of ethanol-ethyl acetate to adjust the solids content of the product to 40%.

例1 ニトログリセリン20%(w/w)を含む前記接着剤溶液
を、シリコン化されたポリエステルフィルムに100μm
の厚さで適用し、溶媒の除去の後、92g/m2の単位面積当
たりの重量を有するフィルムを得た。フィルムを19μm
の厚さのポリエステルフィルムにより被覆し、そして打
抜き、16cm2の接触面積を有する膏薬を形成した(図1
及び2)。420mgの重量を有するこのようにして製造さ
れた皮膚膏薬は55mgのニトログリセリンを含んだ。
Example 1 The adhesive solution containing 20% (w / w) nitroglycerin was applied to a siliconized polyester film by 100 μm.
After removal of the solvent, a film having a weight per unit area of 92 g / m 2 was obtained. 19 μm film
1 mm thick polyester film and punched to form a plaster having a contact area of 16 cm 2 (FIG. 1).
And 2). The skin plaster so prepared having a weight of 420 mg contained 55 mg of nitroglycerin.

インビトロでの活性剤の開放挙動性を評価するため
に、3.14cm2の打抜きされた表面を有する膏薬を、変性F
ranz拡散セル(Chien,Yie W.,Drngs of Today 第23
巻、No.11(1987)625〜646)における毛なしマウスの
皮膚調製物に張り付けた。
To assess the opening behavior of the active agent in vitro, a plaster having a punching 3.14 cm 2 surface, modified F
ranz diffusion cell (Chien, Yie W., Drngs of Today 23rd
Volume, No. 11 (1987) 625-646).

次に、前記セルを、18.00mlの等張リン酸緩衝溶液(3
2±0.5℃)により、すぐに満たし(気泡を有さない)、
そして32±0.5℃に温度調節した。2,4,6及び24時間後、
開放媒体を、32±0.5℃に温度調節された新鮮な溶液に
より交換した。除去された溶液を、HPLCクロマトグラフ
ィーによりそのニトログリセリン含有率について調査し
た(Lit.:Pharm.Biol.4,32(1981))。図3は、16cm2
の大きさの膏薬についての本発明により測定された開放
プロフィールを示す。
Next, the cell was filled with 18.00 ml of an isotonic phosphate buffer solution (3.
2 ± 0.5 ℃), fill immediately (without bubbles),
Then, the temperature was adjusted to 32 ± 0.5 ° C. After 2,4,6 and 24 hours,
The open medium was replaced by a fresh solution temperature-controlled to 32 ± 0.5 ° C. The removed solution was investigated for its nitroglycerin content by HPLC chromatography (Lit .: Pharm. Biol. 4, 32 (1981)). Figure 3 shows a 16cm 2
1 shows the release profile measured according to the invention for plasters of size.

平均のニトログリセリン開放速度(±S.D.)は次の通
りであった(n=3): 2時間後 2.32±0.56mg/16cm2 4時間後 4.42±1.00mg/16cm2 6時間後 6.43±1.33mg/16cm2 24時間後 18.74±2.43mg/16cm2 例2 ポリアクリレート溶液及びニトログリセリンの40%
(w/w)固形分に関して0.8%(w/w)のアセチルアセト
ナトチタン(製造業者:Dynamit Nobel Nederland B.V.,
イソプロパノール中、75%(w/w)溶液)を、20%(w/
w)ニトログリセリンを含む前記接着剤溶液にさらに添
加し、そしてその混合物を均質化した。その溶液を100
μmの厚さを有するシリコン化されたポリエステルフィ
ルムに適用し、溶媒の除去の後、93g/m2の表面重量を有
するフィルムを得た。そのフィルムを19μmの厚さのポ
リエステルフィルムにより被覆し、そして打抜きし、16
cmの接触面積を有する膏薬を得た(図1及び2)。420m
gの重量を有する、そのようにして製造された皮膚膏薬
は55mgのニトログリセリンを含んだ。
Average nitroglycerin opening speed (± SD) were as follows (n = 3): 2 hours after 2.32 ± 0.56mg / 16cm 2 4 hours later 4.42 ± 1.00mg / 16cm 2 6 hours after 6.43 ± 1.33 mg / 16cm 2 24 hours later 18.74 ± 2.43mg / 16cm 2 Example 2 40% of polyacrylate solution and nitroglycerin
(W / w) 0.8% (w / w) titanium acetylacetonato with respect to solids (manufacturer: Dynamit Nobel Nederland BV,
75% (w / w) solution in isopropanol)
w) Added further to the adhesive solution containing nitroglycerin and homogenized the mixture. 100 of the solution
Applying to a siliconized polyester film having a thickness of μm, a film having a surface weight of 93 g / m 2 was obtained after removal of the solvent. The film was covered with a 19 μm thick polyester film and punched out.
A plaster having a contact area of cm was obtained (FIGS. 1 and 2). 420m
The so-prepared skin plaster having a weight of g contained 55 mg of nitroglycerin.

インビトロでの活性物質の開放性を、例2の方法に従
って行なった。図3はまた、その対応する開放プロフィ
ールのグラフを示す。
The in vitro release of the active substance was carried out according to the method of Example 2. FIG. 3 also shows a graph of its corresponding opening profile.

平均のニトログリセリン開放速度(±S.D.)は次の通
りであった(n=3): 2時間後 0.54±0.20mg/16cm2 4時間後 1.20±0.37mg/16cm2 6時間後 1.78±0.53mg/16cm2 24時間後 6.60±1.56mg/16cm2 例3 20%(w/w)ニトログリセリンを含む前記接着剤溶液
を、100μmの厚さを有するシリコン化されたポリエス
テルフィルムに適用し、溶液除去の後、64g/m2の単位面
積当たりの重量を有するフィルムを得た。そのフィルム
を19μmの厚さのポリエステルフィルムにより被覆し、
そして打抜きし、16cm2の接触面積を有する膏薬を得た
(図1及び2)。360mgの重量を有する、そのようにし
て製造された皮膚膏薬は40mgのニトログリセリンを含ん
だ。イソビトロでの活性物質の開放性を、例1の方法に
従って行なった。図3はまた、その対応する開放プロフ
ィールをグラフで示す。
The mean nitroglycerin release rate (± SD) was as follows (n = 3): 0.54 ± 0.20 mg / 16 cm 2 after 2 hours 1.20 ± 0.37 mg / 16 cm 2 after 6 hours 1.78 ± 0.53 mg / 16 cm 2 after 24 hours 6.60 ± 1.56 mg / 16 cm 2 Example 3 Applying the adhesive solution containing 20% (w / w) nitroglycerin to a siliconized polyester film having a thickness of 100 μm and removing the solution After that, a film having a weight per unit area of 64 g / m 2 was obtained. The film was covered with a 19 μm thick polyester film,
Then, punching was performed to obtain a plaster having a contact area of 16 cm 2 (FIGS. 1 and 2). The so-prepared skin plaster having a weight of 360 mg contained 40 mg of nitroglycerin. The release of the active substance in vitro was carried out according to the method of Example 1. FIG. 3 also graphically illustrates the corresponding opening profile.

平均のニトログリセリン開放速度(±S.D.)は、次の
通りであった(n=3): 2時間後 1.27±0.29mg/16cm2 4時間後 2.48±0.48mg/16cm2 6時間後 3.56±0.60mg/16cm2 24時間後 10.79±0.82mg/16cm2
The average nitroglycerin release rate (± SD) was as follows (n = 3): 1.27 ± 0.29 mg / 16 cm 2 after 2 hours 4.48 ± 0.48 mg / 16 cm 2 after 6 hours 3.56 ± 0.60 after 6 hours mg / 16cm 2 After 24 hours 10.79 ± 0.82mg / 16cm 2

───────────────────────────────────────────────────── フロントページの続き (72)発明者 ボイトナー,ディーター ドイツ連邦共和国,デー−4019 モンハ イム,ロルトツィンクベク 52 (72)発明者 クノベルスドルフ,ファウ.ヘニング ドイツ連邦共和国,デー−5300 ボン 3,リュスターシュトラーセ 40 (72)発明者 ボルフ,ハンス−ミヒャエル ドイツ連邦共和国,デー−4019 モンハ イム,リヒャルト−バグナー−シュトラ ーセ 2 (72)発明者 ホフマン,ライナー ドイツ連邦共和国,デー−5450 ノイビ ート 22,ブルクホフシュトラーセ 123 (72)発明者 メコニ,ラインホルト ドイツ連邦共和国,デー−5450 ノイビ ート 11,アレマンネンシュトラーセ 42 (72)発明者 クライン,ロベルト ペーター ドイツ連邦共和国,デー−5450 ノイビ ート 11,ビッキンガーシュトラーセ 3 (56)参考文献 特開 平3−220120(JP,A) ────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Voithner, Dieter Der-4019 Monheim, Lortzinkbek 52 (72) Inventor Knobelsdorf, Fau. Henning Germany 5300 Bonn 3, Lusterstrasse 40 (72) Inventor Wolf, Hans-Michael Germany, Day 4019 Monheim, Richard Bagner-Strasse 2 (72) Inventor Hoffmann, Liner Federal Republic of Germany, Day 5450 Neubit 22, Burghofstrasse 123 (72) Inventor Meconi, Reinhold Federal Republic of Germany, Day 5450 Neubit 11, Alemannenstrasse 42 (72) Inventor Klein, Robert Peter Germany 5450 Neubit 11, Bickingerstrasse 3 (56) References JP-A-3-220120 (JP, A)

Claims (10)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】支持体フィルム、アクリレート−酢酸ビニ
ルコポリマーに基づく、ニトログリセリン含有接着剤及
び使用の前に除去され得る従来の保護フィルムを含んで
成る、ニトログリセリンの経皮投与のための皮膚膏薬で
あって、前記ニトログリセリン含有接着剤が、 1)有機溶媒における、モノマー混合物100重量%に基
づいて酢酸ビニル21〜40重量%、アクリル酸−C2-8−ア
ルキルエステル55〜70重量%及びアクリル酸−C2-4−ヒ
ドロキシルアルキルエステル3〜10重量%を含む混合物
のラジカル重合; 2)有機溶媒における従来の架橋剤及び膏薬の使用に必
要とされる量でのニトログリセリンの混合;及び 3)前記得られた混合物の加熱による架橋及び使用され
る溶媒又は溶媒混合物の除去により製造されることを特
徴とする皮膚膏薬。
1. A skin plaster for transdermal administration of nitroglycerin, comprising a support film, a nitroglycerin-containing adhesive based on an acrylate-vinyl acetate copolymer and a conventional protective film which can be removed before use. Wherein the nitroglycerin-containing adhesive comprises: 1) 21-40% by weight of vinyl acetate, 55-70% by weight of acrylic acid-C 2-8 -alkyl ester, based on 100% by weight of the monomer mixture, in an organic solvent; Radical polymerization of a mixture containing 3 to 10% by weight of acrylic acid- C2-4 -hydroxylalkyl ester; 2) mixing of nitroglycerin in the amount required for the use of conventional crosslinking agents and salves in organic solvents; and 3) A skin plaster prepared by crosslinking the obtained mixture by heating and removing a solvent or a solvent mixture used.
【請求項2】前記アクリル酸−C2-4−ヒドロキシアルキ
ルエステルがヒドロキシエチルアクリレートであること
を特徴とする請求の範囲第1項記載の皮膚膏薬。
2. The skin plaster according to claim 1, wherein said acrylic acid-C 2-4 -hydroxyalkyl ester is hydroxyethyl acrylate.
【請求項3】前記アクリル酸−C2-4−ヒドロキシアルキ
ルエステルが2−ヒドロキシエチルアクリレートであ
り、且つ前記アクリル酸−C2-8−アルキルエステルがエ
チルアクリレートであることを特徴とする請求の範囲第
1項記載の皮膚膏薬。
Wherein the acrylate -C 2-4 - hydroxyalkyl esters are 2-hydroxyethyl acrylate, and said acrylate -C 2-8 - alkyl esters claims, characterized in that ethyl acrylate 2. The skin plaster according to item 1, wherein
【請求項4】前記架橋剤がチタン酸エステル又はその混
合物であることを特徴とする請求の範囲第1〜3のいづ
れか1項記載の皮膚膏薬。
4. The skin plaster according to claim 1, wherein said crosslinking agent is a titanate or a mixture thereof.
【請求項5】架橋のために、架橋剤を含み、そしてラジ
カル重合により得られるコポリマーの重量に基づいて、
0.3〜3重量%のチタン酸エステル又はその混合物が使
用されることを特徴とする請求の範囲第4項記載の皮膚
膏薬。
5. For crosslinking, a crosslinking agent is included and, based on the weight of the copolymer obtained by radical polymerization,
5. A skin plaster according to claim 4, wherein 0.3 to 3% by weight of a titanate or a mixture thereof is used.
【請求項6】前記架橋剤がアセチルアセトナトチタン及
び/又はブチルポリチタネートであることを特徴とする
請求の範囲第4又は5項記載の皮膚膏薬。
6. A skin plaster according to claim 4, wherein said crosslinking agent is acetylacetonato titanium and / or butyl polytitanate.
【請求項7】請求の範囲第1〜6のいづれか1項記載の
膏薬の製造方法であって、膏薬の使用のために必要とさ
れる量でのニトログリセリン及び架橋剤を含み、そして
有機溶媒において、使用されるモノマー混合物の100重
量%に基づいて、21〜40重量%の酢酸ビニル、55〜70重
量%のアクリル酸−C2-8−アルキルエステル及び3〜10
重量%のアクリル酸−C2-4−ヒドロキシルアルキルエス
テルから成るモノマーの混合物のラジカル重合により製
造されるアクリレート−酢酸ビニルコポリマーの溶液
が、膏薬の保護フィルムに、必要とされる層の厚さで適
用され、溶媒又は溶媒の混合物が加熱により除去され、
それによって特定のアクリレート−酢酸ビニルコポリマ
ーが架橋され、その後、支持体フィルムが適用され、そ
して膏薬が必要な大きさに切断され、そして/又は打抜
きされることを特徴とする方法。
7. A method for producing a plaster according to any one of claims 1 to 6, comprising nitroglycerin and a crosslinking agent in the amounts required for the use of the plaster, and an organic solvent. in, based on 100% by weight of the monomer mixture used, 21 to 40 wt% of vinyl acetate, 55 to 70 weight percent acrylic acid -C 2-8 - alkyl esters and 3 to 10
A solution of an acrylate-vinyl acetate copolymer produced by radical polymerization of a mixture of monomers consisting of acrylic acid- C2-4- hydroxyalkyl esters by weight is applied to the protective film of the plaster at the required layer thickness. Applied, the solvent or mixture of solvents is removed by heating,
A method wherein the specific acrylate-vinyl acetate copolymer is crosslinked, after which a support film is applied and the plaster is cut to the required size and / or punched.
【請求項8】前記特定のアクリレート−酢酸ビニルコポ
リマー、ニトログリセリン及び架橋剤を、20〜40重量%
のエタノール又はエタノール−メタノール混合物に一緒
に溶解し、その固形成分が、前記特定のアクリレート−
酢酸ビニルコポリマー、架橋剤及びニトログリセリンの
混合物40〜60重量%から成ることを特徴とする請求の範
囲第7項記載の方法。
8. The method of claim 1, wherein said specific acrylate-vinyl acetate copolymer, nitroglycerin and a crosslinking agent are contained in an amount of 20 to 40% by weight.
In ethanol or an ethanol-methanol mixture, the solid component of which is the specific acrylate-
8. The method according to claim 7, comprising 40 to 60% by weight of a mixture of a vinyl acetate copolymer, a crosslinking agent and nitroglycerin.
【請求項9】前記3)において前記有機溶媒又は溶媒混
合物を実質的に完全に除去することを特徴とする請求の
範囲第1〜6のいづれか1項記載の皮膚膏薬。
9. The skin plaster according to any one of claims 1 to 6, wherein the organic solvent or the solvent mixture is substantially completely removed in the step (3).
【請求項10】前記3)において前記有機溶媒又は溶媒
混合物を加熱により除去することを特徴とする請求の範
囲第1〜6のいづれか1項記載の皮膚膏薬。
10. A skin plaster according to any one of claims 1 to 6, wherein said organic solvent or solvent mixture is removed by heating in said step 3).
JP4510428A 1991-06-10 1992-05-25 Nitroglycerin plaster and method for producing the same Expired - Lifetime JP2579729B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4118891.8 1991-06-10
DE4118891 1991-06-10
PCT/EP1992/001169 WO1992022292A1 (en) 1991-06-10 1992-05-25 Nitroglycerine plaster and process for making it

Publications (2)

Publication Number Publication Date
JPH06506944A JPH06506944A (en) 1994-08-04
JP2579729B2 true JP2579729B2 (en) 1997-02-12

Family

ID=6433497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4510428A Expired - Lifetime JP2579729B2 (en) 1991-06-10 1992-05-25 Nitroglycerin plaster and method for producing the same

Country Status (18)

Country Link
US (1) US5498418A (en)
EP (2) EP0518113A1 (en)
JP (1) JP2579729B2 (en)
KR (1) KR0165875B1 (en)
CN (1) CN1053591C (en)
AT (1) ATE126434T1 (en)
CA (1) CA2109956C (en)
DE (1) DE59203307D1 (en)
DK (1) DK0588839T3 (en)
ES (1) ES2077419T3 (en)
FI (1) FI101854B (en)
GE (1) GEP19991583B (en)
GR (1) GR3017689T3 (en)
HU (1) HU210334B (en)
IE (1) IE67792B1 (en)
NO (2) NO305384B1 (en)
UA (1) UA29400C2 (en)
WO (1) WO1992022292A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
DE4406332C1 (en) * 1994-02-28 1995-06-22 Sanol Arznei Schwarz Gmbh Use of transdermal glyceryl tri:nitrate formulations in pregnancy
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
ES2127711T1 (en) * 1996-12-10 1999-05-01 Rotta Res Bv TRANSDERMAL DRUG ADMINISTRATION SYSTEM FOR THE TREATMENT OF HEART DISEASES.
WO1998025591A1 (en) * 1996-12-10 1998-06-18 Rotta Research B.V. Transdermal drug delivery system for the treatment of heart diseases
CN1070367C (en) * 1997-08-07 2001-09-05 德阳华康药业有限公司 Injection adhesion and method for preparing same
DE19818955C2 (en) * 1998-04-28 2000-06-29 Lohmann Therapie Syst Lts Composition containing polyacrylate, polyterpene, nitroglycerin and optionally polyvinyl acetate
DE19830648A1 (en) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Composition containing glycerol trinitrate, process for its preparation and its use
DE19831418C2 (en) * 1998-07-14 2000-07-06 Lohmann Therapie Syst Lts Method and device for producing flat products from laminate, their transfer to a cover film and final assembly
TR200101790T2 (en) 1998-12-23 2001-10-22 Idea Ag. Formula developed for uncommon in vivo topical applications
PT1031346E (en) 1999-01-27 2002-09-30 Idea Ag NOT INVASIVE VACCINATION THROUGH SKIN
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
MXPA02000053A (en) 1999-07-05 2003-07-21 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers.
JP5021124B2 (en) * 2001-08-29 2012-09-05 日東電工株式会社 Medical adhesive composition, medical adhesive tape and transdermal absorption tape formulation using the same
DK1293198T3 (en) * 2001-09-14 2005-06-06 Sanol Arznei Schwarz Gmbh Transdermal administration device for the treatment of urinary tract disorders
AU2003243896B2 (en) * 2002-05-28 2008-07-03 Labtec Gesellschaft Fur Technologische Forschung Und Entwicklung Mbh Plaster containing fentanyl
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
KR100563194B1 (en) * 2003-11-14 2006-03-21 (주) 에프디엘 Transdermal Dosages Containing Fentanyl as an Active Ingredient
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
US8263680B2 (en) * 2005-09-23 2012-09-11 Henkel Ag & Co. Kgaa Acrylic polymer-based adhesives
WO2007038323A1 (en) * 2005-09-23 2007-04-05 National Starch And Chemical Investment Holding Corporation Acrylic polymer-based adhesives
WO2016032924A1 (en) * 2014-08-25 2016-03-03 Henkel IP & Holding GmbH Acrylic polymers and their use in transdermal drug delivery
CN105362254B (en) * 2015-12-09 2017-03-15 北京邦尼康达医药科技有限公司 A kind of nitroderm TTS and preparation method thereof
DE202016007127U1 (en) 2016-11-22 2016-12-19 Ludwig Volker Fold Softening
CN113125596B (en) * 2021-04-07 2023-01-13 马应龙药业集团股份有限公司 Method for determining related substances in nitroglycerin ointment by high performance liquid chromatography

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
JPS5777617A (en) * 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
JPS5843368B2 (en) 1980-10-30 1983-09-27 日東電工株式会社 Anti-inflammatory analgesic patch
JPS57116011A (en) 1981-01-08 1982-07-19 Nitto Electric Ind Co Ltd Pharmaceutical preparation
JPS6059207B2 (en) 1981-03-13 1985-12-24 日東電工株式会社 Manufacturing method for complex preparations
GB2105990B (en) 1981-08-27 1985-06-19 Nitto Electric Ind Co Adhesive skin patches
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
DE3315272C2 (en) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmaceutical product and process for its manufacture
AU576889B2 (en) 1984-07-24 1988-09-08 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
JPS62292877A (en) * 1986-06-13 1987-12-19 Nippon Shokubai Kagaku Kogyo Co Ltd Adhesive composition
DE3643987A1 (en) 1986-12-22 1988-06-23 Lohmann Therapie Syst Lts BASIC, ACTIVE SUBSTANCE-ADHESIVE ADHESIVE POLYMER, IN PARTICULAR FOR USE WITH BASIC ACTIVE SUBSTANCES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
JPH0696529B2 (en) 1987-03-31 1994-11-30 積水化学工業株式会社 Nitroglycerin patch and method for producing the same
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
JP2524190B2 (en) * 1988-05-11 1996-08-14 日東電工株式会社 Adhesive tape formulation containing clonidine
EP0435199B2 (en) * 1989-12-28 2000-01-19 Nitto Denko Corporation Acrylic gel material and acrylic gel preparation
JP2700835B2 (en) * 1989-12-28 1998-01-21 日東電工株式会社 Acrylic gel material and acrylic gel preparation
JP2882843B2 (en) * 1990-03-28 1999-04-12 日本化薬株式会社 Agent for improving portal hypertension
JPH07116032B2 (en) * 1990-04-06 1995-12-13 積水化学工業株式会社 Nitroglycerin patch

Also Published As

Publication number Publication date
EP0588839B1 (en) 1995-08-16
NO934518L (en) 1993-12-09
HU9303532D0 (en) 1994-04-28
CA2109956A1 (en) 1992-12-23
NO305384B1 (en) 1999-05-25
WO1992022292A1 (en) 1992-12-23
CN1072093A (en) 1993-05-19
EP0588839A1 (en) 1994-03-30
CN1053591C (en) 2000-06-21
IE67792B1 (en) 1996-04-17
FI935522A7 (en) 1993-12-09
NO934518D0 (en) 1993-12-09
CA2109956C (en) 1998-05-05
KR0165875B1 (en) 1999-01-15
DE59203307D1 (en) 1995-09-21
UA29400C2 (en) 2000-11-15
EP0518113A1 (en) 1992-12-16
FI101854B1 (en) 1998-09-15
JPH06506944A (en) 1994-08-04
FI101854B (en) 1998-09-15
IE921863A1 (en) 1992-12-16
US5498418A (en) 1996-03-12
HU210334B (en) 1995-03-28
FI935522A0 (en) 1993-12-09
HUT65979A (en) 1994-08-29
GR3017689T3 (en) 1996-01-31
GEP19991583B (en) 1999-04-29
ES2077419T3 (en) 1995-11-16
DK0588839T3 (en) 1995-12-27
ATE126434T1 (en) 1995-09-15

Similar Documents

Publication Publication Date Title
JP2579729B2 (en) Nitroglycerin plaster and method for producing the same
US4738848A (en) Anti-inflammatory analgesic adhesive preparation
DE10141652B4 (en) Transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives without functional groups and its use
US8128946B2 (en) Medical tape preparation
JP2931002B2 (en) Skin permeation estradiol delivery system
US5368860A (en) Preparation for transdermal drug administration
US5242951A (en) Estrogen-containing gel preparation
US6156335A (en) Preparation with an acrylic-based, adhesive copolymeric matrix for the transdermal delivery of estradiol
JP2002510617A (en) Device for transdermal delivery of diclofenac
JP2001512711A (en) Block copolymer
JP2001517216A (en) Transdermal devices for testosterone delivery
EP1639999A1 (en) Nonaqueous pressure-sensitive adhesive for medicinal tape preparation for percutaneous absorption, medicinal tape preparation for percutaneous absorption, and process for producing the same
JPH10505825A (en) Scopolamine patch
JP2967788B2 (en) Medical adhesive tape and tape preparation for disease treatment
JP4988079B2 (en) Transdermal preparation
JPH0339488B2 (en)
JPS597687B2 (en) medical parts
JP4988078B2 (en) Transdermal preparation
EP0874623A2 (en) Water activatable adhesive matrix containing amethocaine
NO337073B1 (en) Adhesive patch for transdermal administration of a steroid compound, and an adhesive composition of the compound.
JPS5823846B2 (en) Hydrophilic medical components
JP2003089661A (en) Transdermal absorption enhancer of transdermal drug and transdermal drug composition containing the transdermal absorption enhancer
HK1116099B (en) Medical tape preparation
JPH07267860A (en) Eperisone or tolperisone transdermal preparation

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081107

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081107

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081107

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081107

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091107

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091107

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101107

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111107

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111107

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121107

Year of fee payment: 16

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121107

Year of fee payment: 16